Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Journal of clinical pathology - 1 Mar 2010

Gruver Aaron M, Peerwani Ziad, Tubbs Raymond R

Abstract excerpt

Assessment of ERBB2 (HER2) status in breast carcinomas has become critical in determining response to the humanised monoclonal antibody trastuzumab. The current joint College of American Pathologists and the American Society of Clinical Oncology guidelines for the evaluation of HER2 status in breast carcinoma involve testing by immunohistochemistry and fluorescence in situ hybridisation (FISH). However, neither...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to ERBB2 gene
Share to Genes, erbB-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to In Situ Hybridization

Share to In Situ Hybridization, Fluorescence

Source

Open in PubMed Open full text

Identifiers

PMID: 20203220
DOI: 10.1136/jcp.2009.062760
PMCID: PMC2921277

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.PMID 20203220Read ↗

Emerging Technologies for Assessing HER2 AmplificationSemantic proximity Read ↗

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)Semantic proximity Read ↗

Chromogenic In Situ HybridizationSemantic proximity Read ↗

Analytical Validation and Interobserver Reproducibility of EnzMet GeneProSemantic proximity Read ↗

Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithmSemantic proximity Read ↗

Image analysis for bright-field HER2 in situ hybridization: validation for clinical useSemantic proximity Read ↗

Detection of ERBB2 and CEN17 signals in fluorescent in situ hybridization and dual in situ hybridization for guiding breast cancer HER2 target therapySemantic proximity Read ↗

Light weight deep learning-based auto-quantification system for bright-filed HER2 dual in situ hybridization image analysisSemantic proximity Read ↗

Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as modelsSemantic proximity Read ↗

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American PathologistsSemantic proximity Read ↗

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ HybridizationSemantic proximity Read ↗

Comparative Analysis of HER2 Immunohistochemistry (IHC) and Brightfield Dual-Color In Situ Hybridization (DISH) in Lymph Node Metastasized Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.